PROTAC development gains momentum, but clinical performance is poor
Pharmaceutical Technology
FEBRUARY 13, 2023
This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active. GlobalData’s analyst consensus forecast database estimates peak annual sales for ARV-110 of $325 million in 2028.
59 
Let's personalize your content